Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01265745Phase 1Completed

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

Role: lead

NCT01204866Phase 1Completed

Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

Role: lead

NCT00744146Phase 1Completed

First Time in Human Study of Protexia

Role: lead

NCT00964834Phase 1Terminated

Ph1 Study of Valortim and Doxycycline in Humans

Role: lead

NCT00964561Phase 1Suspended

Ph1 Study of Valortim and Ciprofloxacin in Humans

Role: lead

All 5 trials loaded